Review of current treatment practices for carcinoma of the head and neck

Bibliography

• JEMAL A, TIWARI RC, MURRAY T et al.: Cancer Statistics, 2004. CA. Cancer J. Clin. (2004) 54(1):8–29.
   PubMed Web of Science ®Google Scholar
• COHEN EW, LINGEN MW, VOKES EE: The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol. (2004) 22:1743–1752.
   PubMed Web of Science ®Google Scholar
• ••Review of chemotherapeutic options forhead and neck cancer.
   Google Scholar
• SAUNDERS MI, ROJAS AM: Management of cancer of the head and neck — a cocktail with your PORT? N Engl. J. Med. (2004) 350(19):1997–1999.
   Google Scholar
• AL-SARRAF M: Chemotheraputic management of head and neck cancer. Cancer Metastasis Rev. (1987) 6:181–198.
   PubMed Web of Science ®Google Scholar
• VOKES EE, WEICHSELBAUM R, LIPPMAN SM et al.: Head and neck cancer. N Engl. J. Med. (1993) 328(3):184–194.
   PubMed Web of Science ®Google Scholar
• •Review of historical standard therapy for treatment of head and neck cancer.
   Google Scholar
• FORASTIERE A, KOCH W, TROTTI A et al.: Head and neck cancer. N Engl. J. Med. (2001) 345:1890–1900.
   PubMed Web of Science ®Google Scholar
• ••Review of pathophysiology andchemotherapeutic options in head and neck cancer.
   Google Scholar
• LAMONT EB, VOKES EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol. (2001) 2:261–269.
   PubMedGoogle Scholar
• CATIMEL G: Head and neck cancer: guidelines for chemotherapy. Drugs (1996) 51(1):74–88.
   Google Scholar
• CATIMEL G, VERWEJI J, MATTIJSSEN Vet al.: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell
   Google Scholar
• •• carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol (1994) 5(0:533–537.
   Google Scholar
• FORASTIERE AA: Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin. Oncol (1993) 20(4 Suppl. 3):56–60.
   Google Scholar
• FORASTIERE AA, LEONG T, MURPHY B et al.: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. j Clin. Oncol (2001) 19(4):1088–1095.
   PubMed Web of Science ®Google Scholar
• THODTMANN F, THEISS F, KEMMERICH M et al.: Clinical Phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol (1998) 9(3):335–337.
   PubMedGoogle Scholar
• CAPONIGRO F, IONNA F, COMELLA G: New cytotoxic and molecular targeted therapies of head and neck tumors. Curr. Opin. Oncol. (2004) 16(3):225–230.
   PubMedGoogle Scholar
• ••Review of new cytotoxic and targetedtherapies for head and neck cancer.
   Google Scholar
• OCHS JS: Rationale and clinical basis for combining gefitinib (Iressa, ZD 1839) with radiation therapy for solid tumors. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):941–949.
   PubMed Web of Science ®Google Scholar
• SOULIERES D, SENZER NN, VOKES EE et al.: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Clin. Oncol (2004) 22:77–85.
   Web of Science ®Google Scholar
• BASELGA J, AVERBUCH SD: ZD1839 ('Iressa') as an anticancer agent. Drugs (2000) 60:33–40.
   PubMed Web of Science ®Google Scholar
• ZWICK E, BANGE J, ULLRICH A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mot Med. (2002) 8(1):17–23.
   PubMed Web of Science ®Google Scholar
• BUSSED, DOUGHTY RS, RAMSEY TT et al.: Reversible G (1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J. Biol. Chem. (2000) 275:6987–6995.
   PubMedGoogle Scholar
• COHEN E, ROSEN F, STADLER W et al.: Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol (2003) 21(10):1980–1987.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, BASELGA J: Clinical trialdesign and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Canc. Res. (2003) 9:1579–1589.
   PubMed Web of Science ®Google Scholar
• Cohen EW, STENSON K, GUSTIN DM et al.: A Phase II study of 250-mg gefitinib (ZD 1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings from the American Society Clinical Oncology Annual Meeting. Chicago, IL, USA (2003) 22:2021.
   Google Scholar
• SOULIERES D, SENZER NN, VOKES EE et al.: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol (2004) 22:77–85.
   PubMed Web of Science ®Google Scholar
• TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a Phase II study. Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:14.
   Google Scholar
• ROWINSKY EK, WINDLE J, VON HOFF DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol (1999) 17:3631–3652.
   PubMed Web of Science ®Google Scholar
• LEONARD JH, KEARSLEY JH, CHENEVIX-TRENCH G et al.: Analysis of gene amplification in head and neck squamous cell carcinoma. Int. J. Cancer (1991) 48:511–515.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ULLRICH RK, VALERIE KC, CT-JAN W et al.: Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int. J. Radiat. Oncol Biol. Phys. (1994) 29:813–819.
   PubMedGoogle Scholar
• SCHMIDT-ULLRICH RK, MIKKELSEN RB, DENT P et al.: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene (1997) 15:1191–1197.
   PubMed Web of Science ®Google Scholar
• BONNER JA, GIRALT J, HARARI PM et at.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:5507.
   Google Scholar
• KIES MS, ARQUETTE MA, NABELL L et al.: Final report of the efficacy and safety of the anti-epidermal growth factor receptor antibody cetuximab in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proceedings from the American Society Clinical Oncology Annual Meeting. Orlando, FL, USA (2002) 21:925.
   Google Scholar
• CHAN AT, HSU MM, GOH BC: A Phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed a platinum based chemotherapy. Proceedings from the American Society Clinical Oncology Annual Meeting. Chicago, IL, USA (2003) 22:2000.
   Google Scholar
• BASSELGA J, TRIGO JM, BOURHIS Jet al.: Cetuximab (C225) plus cisplatin/ carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on same dose and schedule platinum based regimen. Proceedings from the American Society Clinical Oncology Annual Meeting. Orlando, FL, USA (2002) 21:900.
   Google Scholar
• BURTNESS BA, LI Y, FLOOD Wet al.: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proceedings from the American Society Clinical Oncology Annual Meeting. Orlando, FL, USA (2002) 21:901.
   Google Scholar
• ROONEY M, KISH J, JACOBS J et al: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer (1985) 55:1123–1128.
   PubMed Web of Science ®Google Scholar
• •First study to show the utility of infusional 5-FU and cisplatin in head and neck cancer.
   Google Scholar
• THYSS A, SCHNEIDER M, SANTINI J et al.: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br. J. Cancer (1986) 54(5):755–760.
   PubMedGoogle Scholar
• FORASTIERE AA: Is there a role for induction chemotherapy in the treatment of head and neck cancer? J. NatL Cancer Inst. (2004) 96(22):1647–1649.
   Google Scholar
• PACCEGNELLA A, ORLANDO A, MARCHIORI Get al.: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumor della Testa e del Collo. J. Natl. Cancer Inst. (1994) 86:265–272.
   Google Scholar
• •One of two trials demonstrating improvement in OS using induction therapy in SCCHN.
   Google Scholar
• DOMENGE C, HILL C, LEFEBVRE JL et al.: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br. J. Cancer (2000) 83:1594–1598.
   Google Scholar
• •One of two trials demonstrating improvement in OS using induction therapy in SCCHN.
   Google Scholar
• PIGNON JP, BOURHIS J, DOMENGE C et al.: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MAH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck Cancer. Lancet (2000) 355:949–955.
   Google Scholar
• ZORAT PL, PACCAGNELLA A. CAVANIGLIA G et aL: Randomized Phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J. Nail. Cancer Inst. (2004) 96(22):1714–1717.
   PubMed Web of Science ®Google Scholar
• BROWMAN GP, CRIPPS C, HODSON DI et al.: Placebo controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. (1994) 12:2648–2653.
   PubMed Web of Science ®Google Scholar
• WENDT TG, GRABENBAUER GG, RODEL CM et al.: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol. (1998) 16(4):1318–1324.
   PubMed Web of Science ®Google Scholar
• CALAIS G, ALFONSI M, BARDET E et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Nail. Cancer Inst. (1999) 91(24):2081–2086.
   PubMed Web of Science ®Google Scholar
• BRIZEL DM, ALBERS ME, FISHER SR et al.: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Eng/. J. Med. (1998) 338(25):1798–1804.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the benefit of chemotherapy combined with hyperfractionated irradiation.
   Google Scholar
• ADELSTEIN DJ, ADAMS GL, LI Yet al.: An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. (2003) 21(1):92–98.
   Google Scholar
• ••Only study to compare a cisplatin plus RTarm versus cisplatin/5-FU/RT arm for the treatment of head and neck cancer.
   Google Scholar
• BERNIER J, DOMENGE C, OZSAHIN M et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N EngL J. Med. (2004) 350(19):1945–1952.
   PubMed Web of Science ®Google Scholar
• ••Only trial to show an OS advantage withadjuvant chemoradiotherapy for fully resected head and neck cancer.
   Google Scholar
• COOPER JS, PAJAK, TF, FORASTIERE AA et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N EngL J. Med. (2004) 350(19):1937–1944.
   PubMedGoogle Scholar
• MORTON RP, RUGMAN F, DORMAN EB et al.: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial Phase III controlled trial. Can. Chem. Pharm. (1985)15:283–289.
   PubMed Web of Science ®Google Scholar
• KOWALSKI LP, CARVALHO AL: Natural history of untreated head and neck cancer. Eur. J. Cancer (2000) 36:1032–1037.
   PubMed Web of Science ®Google Scholar
• JACOBS C, GOFFINET DR, GOFFINET Let al.: Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer: a report from the Northern California Oncology Group. Cancer (1987) 60:1178–1183.
   Google Scholar
• DEPARTMENT OF VETERANS AFFAIRS LARYNGEAL CANCER STUDY GROUP: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N EngL J. Med. (1991) 324:1685–1690.
   PubMed Web of Science ®Google Scholar
• •First large randomised study to demonstrate the larynx-sparing capabilities of chemoradiation.
   Google Scholar
• LEFEBVRE J, CHEVALIER D, LUBOINSKI B et al.: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J. Natl. Cancer Inst. (1996) 88:890–899.
   PubMed Web of Science ®Google Scholar
• FORASTIERE AA, GOEPFERT H, MAOR M et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N EngL J. Med. (2003) 349:2091–2098.
   PubMed Web of Science ®Google Scholar
• ••Study that confirmed CCRT as the initialmodality treatment of resectable laryngeal cancer.
   Google Scholar
• DEVITA VT, HELLMAN S, ROSENBERG SA: Cancer: principle and practice of oncology. In: Cancer of the Head and Neck. Lippincott Williams and Wilkins, Philadelphia, PA, USA (2001):789–915.
   Google Scholar
• FORASTIERE AA, MITCH B, SCHULLER DE et al.: Randomized comparison of cisplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. (1992) 10(01245–1251.
   PubMed Web of Science ®Google Scholar
• •Pivotal study that changed the standard of care to a cisplatin-containing regimen for the treatment of locally advanced head and neck cancer.
   Google Scholar
• BROWMAN GP, CRONIN L: Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin. Oncol. (1994) 21:311–319.
   PubMed Web of Science ®Google Scholar
• ROONEY M, KISH J, JACOBS J et al.: Improved complete respnonse rate and survival in advanced head and neck cancer after three course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer (1985) 55:1123–1128.
   PubMed Web of Science ®Google Scholar
• LEE DJ, COSMATOS D, MARCIAL VA et al.: Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (1995) 32:567–576.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOGAERT W, VAN DER SCHUEREN E, HORJOT C et al.: Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int. J. Radiat. Oncol. BioL Phys. (1986) 12:587–591.
   Google Scholar
• OVERGAARD J, SAND HANSEN H, OVERGAARD M et al.: A randomized double-blind Phase III study of nimorazole as hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. (1998) 46:135–146.
   PubMed Web of Science ®Google Scholar
• SYKES AJ, SLEVIN NJ, MACDOUGALL RH et al.: Results of a Phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiother. Oncol. (2004) 71:81–84.
   PubMed Web of Science ®Google Scholar
• PETROVICH A, PARKER RG, LUXTON G et al.: Carcinoma of the lip and selected sites of the head and neck skin. A clinical study of 896 patients. Radiother. Oncol. (1987) 8:11–17.
   Google Scholar
• CEREZO L, LIU FF, TSANG R, PAYNE D: Squamous cell carcinoma of the lip: analysis of the Princess Margaret experience. Radiother. Oncol. (1993) 28:142–147.
   PubMedGoogle Scholar
• MARSIGLIA H, HATE-MEDER C, SASSO G et al.: Brachytherapy for T1-2 floor-of-the-mouth cancers: The Gustave-Roussy Institute experience. Int. J. Radiat. Oncol. Biol. Phys. (2002) 52:1257–1263.
   PubMed Web of Science ®Google Scholar
• MAZERON JJ, SIMON JH, LEPECHOUX C et al.: Effect of dose rate on local control and complications in definite irradiation of T1-T2 squamous cell carcinomas of mobile tongue and floor of the mouth with interstitial Iridium-192. Radiother. Oncol. (1991) 21(1):39–47.
   PubMedGoogle Scholar
• FEIN DA, MENDENHALL WM, PARSON JT et al.: Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery. Head Neck (1994) 16:358–365.
   PubMedGoogle Scholar
• MAZERON JJ, CROOK JM, BENCK V et al.: Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue. Int. J. Radiat. Oncol. Biol. Phys. (1990) 19:1369–1376.
   PubMed Web of Science ®Google Scholar
• WANG CC, KELLY J, AUGUST M, DONOFF B: Early carcinoma of the oral cavity: a conservative approach with radiation therapy./ Oral Maxillofac. Surg. (1995) 53:687–690.
   PubMedGoogle Scholar
• MENDENHALL WM, AMDUR RJ, MORRIS CG et al.: T1-T2NO squamous cell carcinoma of the glottic larynx treated with radiation therapy. J. Clin. Oncol. (2001) 50:953.
   Google Scholar
• LE QT, FU KK, KROLL S et al.: Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39:115–126.
   PubMed Web of Science ®Google Scholar
• SPECTOR JG, SESSIONS DG, CHAO KS et al.: Stage I (T1NO) squamous cell carcinoma of the laryngeal glottis; therapeutic results and voice preservation. Head Neck. (1999) 21:707–717.
   PubMedGoogle Scholar
• HINERMAN RW, MENDENHALL WM, AMDUR RJ: Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. Head Neck (2002) 24:456–467.
   PubMedGoogle Scholar
• AMDUR RJ, MENDENHALL WM, PARSON JT et al.: Carcinoma of the soft palate treated with irradiation: analysis of results and complications. Radiother. Oncol. (1987) 9:185–194.
   PubMedGoogle Scholar
• REMMLER D, MEDINA JE, BYERS RM et al.: Treatment of choice for squamous carcinoma of the tonsillar fossa. Head Neck Surg-. (1985) 7:206–211.
   PubMedGoogle Scholar
• MAZERON JJ, CROOK J, MARTIN M et al.: Iridium 192 implantation of squmaous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (1990) 19:1369–1376.
   PubMed Web of Science ®Google Scholar
• MENDENHALL WM, AMDUR RJ, STRINGER SP et al.: Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? J. Clin. Oncol. (2000) 18:2219–2225.
   Google Scholar
• HARRISON LB, LEE H, KRAUS DH et al.: Long term results of primary radiation therapy for squamous cancer of the base of tongue. Radiother. Oncol. (1996) 39:S6 (Abstract).
   Google Scholar
• HOUSSET M, BAILLET F, DESSARD-DIANA B et al.: A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. Int. J. Radiat. Oncol. Biol. Phys. (1987) 13:511–516.
   PubMed Web of Science ®Google Scholar
• MENDENHALL WM, PARSONS JT, STRINGER SP et al.: Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery. Int. J. Radiat. Oncol. Biol. Phys. (1993) 27:1017–1027.
   PubMedGoogle Scholar
• HARRISON LB, ZELEFSKY MJ, ARMSTRONG JG et al.: Performance status after treatment for squamous cell cancer of the base of tongue: a comparison of primary radiation therapy versus surgery. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30:953–957.
   PubMed Web of Science ®Google Scholar
• AMDUR RJ, MENDENHALL WM, STRINGER SP et al.: Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus. Head Neck (2001) 23(5):353–362.
   PubMedGoogle Scholar
• HARRISON LB, SOLOMON B, MILLER S et al.: Prospective computer-assisted voice analysis for patients with early stage glottic cancer: a preliminary report of the functional result of laryngeal irradiation. Int. J. Radiat. Oncol. Biol. Phys. (1990) 19:123–127.
   PubMed Web of Science ®Google Scholar
• HARAF DJ, ROSEN FR, STENSON K et al.: Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin. Cancer Res. (2003) 9:5936–5943.
   PubMed Web of Science ®Google Scholar
• CHAO KS, MAJHAIL M, HUANG CJ et al.: Intensity modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother. Oncol. (2001) 61:275–280.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the benefit of IMRT in terms of salivary preservation in oropharynegeal cancer.
   Google Scholar
• LEE N, XIA P, QUIVEY JM: Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Intl. Radiat. Oncol. Biol. Phys. (2002) 53:12–21.
   PubMed Web of Science ®Google Scholar
• •Largest experience of IMRT in nasopharyngeal cancer.
   Google Scholar
• CHAO KS, OZYIGIT G, TRAN BN: Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. (2003) 55:312–321.
   PubMed Web of Science ®Google Scholar
• WU Q, MANNING M, SCHMIDT-ULLRICH R et al.: The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int. Radiat. Oncol. Biol. Phys. (2000) 46:195–205.
   PubMed Web of Science ®Google Scholar
• LIN A, KIM HM, TERRELL JE et al.: Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57:61–70.
   PubMed Web of Science ®Google Scholar
• WU Q, MOHAN R, MORRIS M et aL: Simulateous integrated boost intensity- modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. Int. J. Radiat. Oncol Biol. Phys. (2003) 56:573–585.
   PubMed Web of Science ®Google Scholar
• FU KK, PAJAK TF, TROTTI A: A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol Biol Phys. (2000) 48:7–16.
   PubMed Web of Science ®Google Scholar
• •Important study that demonstrates the benefits of dose-intensification of RT for the treatment of head and neck cancer.
   Google Scholar
• JEREMIC B, SHIBAMOTO Y, MILICIC B: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. (2000) 18:1458–1464.
   PubMed Web of Science ®Google Scholar
• HARRISON LB, RABEN A, PFISTER D: A prospective Phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck (1998) 20:497–503.
   PubMedGoogle Scholar
• CHMURA SJ, MILANO MT, HARAF DJ: Reirradiation of recurrent head and neck cancers with curative intent. Semin. Oncol (2004) 6:816–821.
   Google Scholar
• DE CREVOISIER R, BOURHIS J, DOMENGE C et al.: Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J. Clin. Oncol. (1998) 16:3556–3562.
   PubMed Web of Science ®Google Scholar
• MILANO MT, VOKES EE, STENSON KM et al.: Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel and fluorouracil chemotherapy. Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004):5510.
   Google Scholar
• DE CREVOISIER R, DOMENGE C, WIBAULT P et al.: Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer (2001) 91:2071–2076.
   PubMed Web of Science ®Google Scholar
• MACHTAY M, ROSENTHAL DI, CHALIAN AA. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and- neck cancer. Int. J. Radiat. Oncol Biol. Phys. (2004) 59:72–77.
   Google Scholar
• LEIBEL SA, FUKS Z, ZELEFSKY MJ et al.: Intensity-modulated radiotherapy. Cancer J. (2002) 8:164–176.
   PubMed Web of Science ®Google Scholar
• •Review of IMRT technology and implementation.
   Google Scholar
• XING L, WU Q, YANG Yet al: Physics of IMRT. In: IMRT A Clinical Perspective. AJ Mundt, JC Roeske (Eds). BC Decker Toronto, Canada (2005).
   Google Scholar
• FURIE B, CASSILETH PA, ATKINS MB et al.: Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment. TS Lawrence, GT Henning (Eds). Elsevier Philadelphia, PA, USA:355 (2003).
   Google Scholar
• WORDEN FP, MOON J, SAMLOWSKI Wet al.: A Phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:5512.
   Google Scholar
• VERMOKEN JB, REMENAR E, VAN HERPEN Get al.: Standard cisplatin/ infusional 5-fluorouracil (PF) versus docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck: A Phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971). Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:5508.
   Google Scholar
• ROBBINS KT, MEDINA JE, WOLFE GT et al.: Standardizing neck dissection terminology: official report of the Academy's Committee for Head Neck Surgery and Oncology. Arch. Otolaryngol Head Neck Surg (1991) 117:601–605.
   PubMedGoogle Scholar
• COOPER JS, PAJAK TF, FORASTIERE A et al.: Precisely defining high-risk operable head and neck tumors based on RTOG 85–03 and 88–24: targets for postoperative radiochemotherapy? Head Neck (1998) 20:588–594.
   Google Scholar
• POSNER MR, GLISSON B, FRENETTE G et al.: Multicenter Phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol (2001) 19:1091–1104.
   Google Scholar
• SCHRIJVERS D: Phase I-II trial of docetaxel, cisplatin and fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Proceedings from the American Society Clinical Oncology Annual Meeting. Atlanta, GA, USA (1999) 18:394q.
   Google Scholar
• VOKES EE, STENSON K, ROSEN FR et al.: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. (2003) 21:320–326.
   PubMed Web of Science ®Google Scholar
• ARGIRIS A, Stenson KM, Brockstein BE et al.: Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck (2004) 26:447–455.
   PubMedGoogle Scholar
• MCHAM SA, ADELSTEIN DJ, RYBICKI LA et al.: Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck (2003) 25:791–798.
   Google Scholar
• STENSON KM, HARAF DJ, PELZER H et al.: The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: The feasibility of selective neck dissection. Arch. Otolaryngol Head Neck Surg. (2000) 126:950–956.
   PubMedGoogle Scholar
• LAVERTU P, ADELSTEIN DJ, SAXTON JP et al.: Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck (1997) 19:559–566.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, JOHNSON CJ, MORRISON W et al.: The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch. Otolaryngol. Head Neck Surg. (2001) 127:135–139.
   PubMedGoogle Scholar
• LACCOURREYE O, BRASNU D, BIACABE B et al.: Neoadjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3-T4:5-year oncologic results. Head Neck (1998) 20:595–599.
   PubMedGoogle Scholar
• KLUG C, WUTZL A. KERMER Get al.: Neck dissection in the combined modality therapy of patients with locoregionally advanced head and neck cancer. Int. J. Oral Mmcillofac. Surg. (2005) 34:143–148.
   Google Scholar
• HITT R, LOPEZ-POUSA A, RODRIGUEZ M et al.: Phase III trial comparing cisplatin and 5-fluorouracil versus cisplatin, 5-fluorouracil and paclitaxel as induction therapy in locally advanced head and neck cancer. Proceedings from the American Society Clinical Oncology Annual Meeting. Chicago, IL, USA (2003) 22:1997.
   Google Scholar
• VERMORKEN JB, REMENAR E, VAN HERPEN J et al.: Standard cisplatin/ infitsional 5-fluorouracil (PF) versus docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a Phase III trial of the EORTC Head Neck Cancer Group (EORTC 24971). Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:5508.
   Google Scholar
• SONG J, CHEN C, RABEN D et al.: Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology (2004) 18(14):1757–1777. Review of new cytotoxic and targeted therapies for head and neck cancer.
   Google Scholar
• KIES MS, CLAYMAN GL, EL-NAGGAR AK et al.: Induction therapy with 5CH66336, a farnesyl transferase inhibitor, in squamous cell carcinoma of the head and neck. Proceedings from the American Society Clinical Oncology Annual Meeting. San Francisco, CA, USA (2001):896.
   Google Scholar
• MAUER AM, COHEN EE, WONG SJ et al.: Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings from the American Society Clinical Oncology Annual Meeting. New Orleans, LA, USA (2004) 22:5539.
   Google Scholar